Sign in
Not yet recruitingPhase 2

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Key facts

Who runs it
Kirby Institute
Where
Australia5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
Sept 2026
Expected to end
Mar 2027
Type of study
Interventional
Treatments tested
  • 12 weeks of weekly subcutaneous semaglutide injection
Record updated
26 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Has provided voluntary, written informed consent
  • Aged 18 years or older
  • Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria)
  • Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine
  • Willing and able to comply with study procedures and follow-up visits
  • People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end

Who cannot take part

  • Currently taking a GLP-1 receptor agonist
  • Uncontrolled medical or psychiatric conditions that may interfere with participation
  • Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information
  • History of pancreatitis
  • History of medullary thyroid cancer
  • Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data
  • Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c >6.5 at screening)
  • Body mass index less than 22 kg/m2
  • Current enrolment in another interventional trial
  • Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy
  • Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures
  • Currently experiencing psychosis or current active suicidality

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

The group in the trial

  • Adults with methamphetamine use disorderTreatment being tested

    12 weeks of subcutaneous semaglutide administered once weekly

    Treatment: 12 weeks of weekly subcutaneous semaglutide injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 June 2026